Elevated thrombin activatable fibrinolysis inhibitor levels in women with polycystic ovary syndrome.
The aim of the present study was to evaluate plasma concentrations of thrombin activatable fibrinolysis inhibitor (TAFI) in relation with hormonal, metabolic, and hemostatic profile in patients with and without polycystic ovary syndrome (PCOS). A total of 38 women with PCOS and 37 age and body mass index (BMI) matched controls were eligible for the study. Hirsutism scores, hormonal, metabolic, and hemostatic profile as well as TAFI levels were evaluated in each subject. Women with PCOS exhibited higher plasma concentrations of TAFI levels than controls (107.42 ± 34.77% versus 91.86 ± 23.88%, p = 0.027). TAFI levels were significantly correlated positively with BMI, fasting insulin levels, modified Ferriman Gallwey scores and Homeostasis Model Assessment (HOMA) index, systolic blood pressure, and waist and hip circumferences, whereas negatively correlated with activated partial thromboplastin time (p < 0.05). However, after adjustment for all possible confounding factors, none of the parameters was significantly deterministic on TAFI levels. The data of the present study suggested that plasma TAFI levels were higher in women with PCOS as compared with healthy age and BMI-matched controls, indicating impaired fibrinolysis. This hypofibrinolytic state may be responsible for the increased cardiovascular disease risk in women with PCOS.